Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MIA3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MIA3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MIA3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MIA3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MIA3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819311 | Liver | Cirrhotic | Golgi vesicle transport | 153/4634 | 296/18723 | 1.02e-23 | 6.43e-21 | 153 |
GO:000688811 | Liver | Cirrhotic | endoplasmic reticulum to Golgi vesicle-mediated transport | 77/4634 | 130/18723 | 5.78e-17 | 7.56e-15 | 77 |
GO:001605011 | Liver | Cirrhotic | vesicle organization | 133/4634 | 300/18723 | 7.35e-14 | 6.41e-12 | 133 |
GO:000690012 | Liver | Cirrhotic | vesicle budding from membrane | 41/4634 | 61/18723 | 3.12e-12 | 2.25e-10 | 41 |
GO:00709724 | Liver | Cirrhotic | protein localization to endoplasmic reticulum | 45/4634 | 74/18723 | 4.79e-11 | 2.73e-09 | 45 |
GO:004206012 | Liver | Cirrhotic | wound healing | 155/4634 | 422/18723 | 2.12e-08 | 7.56e-07 | 155 |
GO:009011411 | Liver | Cirrhotic | COPII-coated vesicle budding | 21/4634 | 29/18723 | 8.97e-08 | 2.63e-06 | 21 |
GO:00070292 | Liver | Cirrhotic | endoplasmic reticulum organization | 42/4634 | 87/18723 | 1.67e-06 | 3.22e-05 | 42 |
GO:003545911 | Liver | Cirrhotic | vesicle cargo loading | 15/4634 | 27/18723 | 5.96e-04 | 4.63e-03 | 15 |
GO:00901101 | Liver | Cirrhotic | COPII-coated vesicle cargo loading | 10/4634 | 15/18723 | 7.26e-04 | 5.36e-03 | 10 |
GO:000166712 | Liver | Cirrhotic | ameboidal-type cell migration | 145/4634 | 475/18723 | 2.23e-03 | 1.36e-02 | 145 |
GO:00106317 | Liver | Cirrhotic | epithelial cell migration | 110/4634 | 357/18723 | 5.14e-03 | 2.65e-02 | 110 |
GO:00026876 | Liver | Cirrhotic | positive regulation of leukocyte migration | 47/4634 | 135/18723 | 5.55e-03 | 2.81e-02 | 47 |
GO:00901327 | Liver | Cirrhotic | epithelium migration | 110/4634 | 360/18723 | 6.79e-03 | 3.35e-02 | 110 |
GO:00901307 | Liver | Cirrhotic | tissue migration | 111/4634 | 365/18723 | 7.66e-03 | 3.61e-02 | 111 |
GO:00071624 | Liver | Cirrhotic | negative regulation of cell adhesion | 93/4634 | 303/18723 | 1.06e-02 | 4.66e-02 | 93 |
GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
GO:000688821 | Liver | HCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 100/7958 | 130/18723 | 1.15e-15 | 8.67e-14 | 100 |
GO:001605021 | Liver | HCC | vesicle organization | 194/7958 | 300/18723 | 5.58e-15 | 3.97e-13 | 194 |
GO:000690021 | Liver | HCC | vesicle budding from membrane | 53/7958 | 61/18723 | 7.38e-13 | 3.80e-11 | 53 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MIA3 | SNV | Missense_Mutation | | c.1863N>T | p.Glu621Asp | p.E621D | Q5JRA6 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MIA3 | SNV | Missense_Mutation | | c.3776C>G | p.Ser1259Cys | p.S1259C | Q5JRA6 | protein_coding | deleterious(0.03) | probably_damaging(0.94) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MIA3 | SNV | Missense_Mutation | novel | c.2476N>C | p.Glu826Gln | p.E826Q | Q5JRA6 | protein_coding | tolerated(0.13) | benign(0.131) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MIA3 | SNV | Missense_Mutation | novel | c.3970N>A | p.Glu1324Lys | p.E1324K | Q5JRA6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MIA3 | SNV | Missense_Mutation | | c.1836N>T | p.Glu612Asp | p.E612D | Q5JRA6 | protein_coding | tolerated(0.12) | possibly_damaging(0.681) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MIA3 | SNV | Missense_Mutation | rs199732400 | c.1159A>G | p.Ile387Val | p.I387V | Q5JRA6 | protein_coding | tolerated(0.57) | benign(0) | TCGA-B6-A2IU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MIA3 | SNV | Missense_Mutation | | c.4900G>A | p.Ala1634Thr | p.A1634T | Q5JRA6 | protein_coding | tolerated(0.05) | possibly_damaging(0.802) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MIA3 | SNV | Missense_Mutation | | c.3496N>C | p.Asp1166His | p.D1166H | Q5JRA6 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MIA3 | SNV | Missense_Mutation | | c.815N>G | p.Thr272Ser | p.T272S | Q5JRA6 | protein_coding | tolerated(0.38) | benign(0.031) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MIA3 | SNV | Missense_Mutation | | c.1276G>A | p.Gly426Arg | p.G426R | Q5JRA6 | protein_coding | tolerated(0.48) | benign(0.009) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |